Bacillus of Calmette and Guerin (BCG) Versus Gemcitabine For Intravesical Therapy In High Risk Superficial Bladder Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
A significant number of patients with high risk superficial bladder cancer has progression to
invasive disease. No consensus exists regarding the optimal treatment to decrease the
recurrence and progression rate. The aim of this research is to evaluate the safety,
tolerability and efficacy of adjuvant intravesical gemcitabine vs. BCG in the treatment of
high-risk superficial bladder cancer